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Abstract
Signal transducers and activators of transcription 5(STAT5) are cytokine induced signaling proteins, which regulate key
immunological processes, such as tolerance induction, maintenance of homeostasis, and CD4 T-effector cell differentiation.
In this study, transcriptional targets of STAT5 in CD4 T cells were studied by Chromatin Immunoprecipitation (ChIP).
Genomic mapping of the sites cloned and identified in this study revealed the striking observation that the majority of
STAT5-binding sites mapped to intergenic (.50 kb upstream) or intronic, rather than promoter proximal regions. Of the 105
STAT5 responsive binding sites identified, 94% contained the canonical (IFN-c activation site) GAS motifs. A number of
putative target genes identified here are associated with tumor biology. Here, we identified Fos-related antigen 2 (FRA2) as
a transcriptional target of IL-2 regulated STAT5. FRA2 is a basic -leucine zipper (bZIP) motif ‘Fos’ family transcription factor
that is part of the AP-1 transcription factor complex and is also known to play a critical role in the progression of human
tumours and more recently as a determinant of T cell plasticity. The binding site mapped to an internal intron within the
FRA2 gene. The epigenetic architecture of FRA2, characterizes a transcriptionally active promoter as indicated by enrichment
for histone methylation marks H3K4me1, H3K4me2, H3K4me3, and transcription/elongation associated marks H2BK5me1
and H4K20me1. FRA2 is regulated by IL-2 in activated CD4 T cells. Consistently, STAT5 bound to GAS sequence in the
internal intron of FRA2 and reporter gene assays confirmed IL-2 induced STAT5 binding and transcriptional activation.
Furthermore, addition of JAK3 inhibitor (R333) or Daclizumab inhibited the induction in TCR stimulated cells. Taken
together, our data suggest that FRA2 is a novel STAT5 target gene, regulated by IL-2 in activated CD4 T cells.
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Introduction
Signal transducers and activators of transcription STAT5a and
STAT5b (collectively called STAT5) are highly homologous
proteins that are encoded by two separate genes and are activated
by Janus-activated kinases (JAK) downstream of cytokine recep-
tors. STAT proteins are activated by a wide variety of cytokines,
all of which use the JAK-STAT signalling pathway as their main
mode of signal transduction [1]. Upon activation by cognate JAKs,
STAT proteins, dimerize and translocate into the nucleus where
they bind to the promoters of genes containing the consensus
recognition motif (GAS motif-TTCN3GAA) resulting in the
transcriptional regulation of target genes.
Several studies have shown that STAT5 proteins regulate
multiple genes primarily involved in T cell survival, proliferation,
differentiation and homeostasis, either by transcriptional activa-
tion or repression by recruitment of negative regulatory cofactors
[2]. Given its critical role in vital cellular processes, major efforts
have been made to identify direct cellular targets of STAT5 using
techniques such as ChIP-chip and ChIP-seq techniques [3,4,5].
However, the target genes identified by STAT5-ChIP differ
between cell types and are further influenced by cell treatments
and time points studied [6,7]. Thus, the range of target genes that
STAT5 regulates may differ from one cell to another, from one
cell treatment to another as well as being dependant on the time
point studied. Nevertheless, these studies have begun to provide
important mechanistic insights into the regulation of various
biological and cellular processes by STAT5.
In this study, we aimed to identify genes regulated by IL-2/
STAT5 in preactivated CD4 T cells by ChIP, with a view to
understanding the range of STAT5 target genes and the molecular
actions regulated by IL-2 in this cell type. Analysis of the target
sites provided an insight at various levels, such as relative
positioning with respect to the transcription start site (TSS) of
genes, with only a small percentage (11%) within 10 kb of the TSS
of gene/s; presence/absence of GAS sequences, which revealed
that 94% contained the consensus/non-consensus recognition
motif; epigenetic changes associated with mapped sites; identifi-
cation of putative downstream-target genes and hence the
potential cellular processes and biological pathways that may be
regulated by STAT5.
Previously, it was shown that IL-2 and STAT5 plays a
prominent role in human and murine TH2 cell differentiation
and we recently showed that c-maf is an IL-2 induced STAT5
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target gene that is involved in this process [4,8,9,10]. In keeping
with the Th2 theme for IL-2/STAT5, here we present the
characterization of the FRA2 as a STAT5 target gene, identified
from the ChIP cloning studies. In the immune system, FRA2 is
involved in IL-4 gene regulation and is involved in CD4-Th2 cell
differentiation [11]. More recently, FRA2 has been documented as
a key determinant of cellular plasticity during CD4 T cell
differentiation [12]. FRA2 is a member of the FOS/JUN
subgroup of bZIP transcription factors (TFs) and the AP1
transcription factor complex, which consists of heterodimers
formed by the Fos family (c-FOS, FOSB, FRA1, and FRA2) with
Jun family (c-JUN, JUNB and JUND) of transcription factors
[13,14]. AP1 complexes are able to activate or suppress the
expression of many genes involved with proliferation, differenti-
ation, and survival: functions in common with STAT5. Consistent
with its role in vital cellular functions, dysregulated expression of
FRA2 has also been associated with lymphomas [15].
In this study, we identify one of the ChIP-cloned sequences to
map to an internal intronic region of the FRA2 gene, and show
that FRA2 is induced by T –cell receptor activation in human CD4
T cells in an IL-2/JAK3/STAT5 dependent manner.
Materials and Methods
Human blood CD4 T cell isolation and culture conditions
PBMCs were isolated by density gradient centrifugation from
heparinized buffy coat obtained from the National Blood Service
(St. George’s Hospital, London). CD4 T cells were isolated by
positive selection from the PBMCs using CD4 microbeads and
(Miltenyi Biotec, Auburn, CA) an LS column as described in the
manufacturer’s instructions. Cells were maintained in RPMI 1640
medium (PAA Laboratories, Yeovil, UK) with 10% fetal bovine
serum (FBS, PAA laboratories), 2 mM L-glutamine and penicillin-
streptomycin (100 IU/ml and 100 mg/ml, Sigma-Aldrich, UK).
The freshly isolated CD4 T cells were either used immediately or
activated with PHA 2 mg/ml (EY Laboratories, San Mateo,CA)
for 72 hours to generate PHA blasts. The PHA blasts were rested
for 16 hours in complete RPMI 1640 medium before restimula-
tion. Where appropriate, cells were stimulated with 100 U/ml IL-
2 (TECIN, [Teceleukin]; Roche) for 20 minutes or as stated for
activation kinetics experiments. In other experiments, CD4 T cells
were activated with plate bound anti-CD3 (UCHT1; 10 mg/ml)
and soluble anti-CD28 Ab (2 mg/ml; Ancell, Bayport, MN) with or
without the JAK3 inhibitor R333 (5 mM; a gift from Rigel
Pharmaceuticals, South San Francisco) or humanized anti-Tac
(HAT, or Daclizumab (Zenapax), 10 mg/ml, Roche, Nutley, NJ).
Chromatin Immunoprecipitation, Cloning and
Sequencing
Chromatin immunoprecipitation (ChIP) cloning experiments
were performed using 1.56107 CD4 T cells stimulated with IL-2
for 20 min followed by a 10-min crosslink with formaldehyde
(0.37%) at 37uC and immediate termination of the reaction by the
addition of 1.25 M glycine, as previously described [6]. The cells
were harvested and shearing of the chromatin was done on a
Misonix 3000 sonicator. The sonicated chromatin was immuno-
precipitated for an hour using mMACS protein A microbeads
(Miltenyi Biotec, UK) and anti-STAT5a and -STAT5b monoclo-
nal antibodies or control mouse IgG Abs (all from Zymed
Laboratories, UK). Purified chromatin was blunt-end repaired
using T4 DNA polymerase (New England Biolabs, UK), ligated to
linkers, PCR amplified, and cloned into TOPO vector (Invitrogen,
UK) and sequenced (Cogenics, UK). Validation and confirmation
of the GAS sequence within the FRA2 gene, as a STAT5 target
was done by quantitative PCR reaction, performed as described in
the LowCell# ChIP Kit TM (Diagenode, UK) and data
interpreted as a percentage of the starting material (Input).
In silico mapping and screening of cloned sequences
Individual clones were blasted against the UCSC Genome
Browser (http://genome.ucsc.edu) and the public databases at
NCBI using the BLAST tool (http://www.ncbi.nlm.nih.gov/) and
filtered for 100% identity.
The sequences were screened for closest genes and conservation
tracks using the March 2006 (hg 18) human reference sequence
(NCBI Build 36.1). Additionally, the sequences were mapped to
the whole genome analysis of DNase-I Hypersensitivity sites in
CD4 T-cells using the May 2004 (hg17) human reference
sequence (NCBI Build 35) [16]. Gene ontology analyses of all
the cloned sequences were performed using the PANTHER
database [17].
RNA isolation, cDNA synthesis and RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen Life
Technologies, CA, USA). 500 ng of total RNA was reverse-
transcribed to cDNA using the TaqMan Reverse Transcription kit
(Life Technologies) following manufacturer’s instructions. The
first-strand cDNA obtained using the above protocol was amplified
using different primer/probe mix in 384-well plates using the ABI
Prism 7900 HT Sequence Detection System (Applied Biosystems,
Foster City, CA). The sequence detector SDS 2.3 software
(Applied Biosystems) was used to export the Ct values. 18S gene
expression was used as the endogenous reference gene. Quanti-
fication was done by applying the following equation: RQ=22DCt
where RQ represents the estimated amplification assuming a
doubling of material during each PCR cycle and DCt is the
Ct(gene)-Ct(18 s) and Ct is the cycle at which the threshold is
crossed.
Cell transfection and luciferase reporter assays
HEK293T cells were transfected to reconstitute IL-2R signal-
ling using the calcium phosphate method, as previously described
[18]. Trimerized GAS1 sequence was synthesized (Sigma, UK),
cloned into pGL4.23 (luc2/minP) vector (Promega, UK), and
verified by sequencing (Eurofins MWG-Operon, Germany). 2 mg
of IL-2 receptor b chain, 0.5 mg of common cytokine receptor c
chain, 0.25 mg of JAK3, and 75 ng of each of the Stat5 plasmids,
0.5 ng of the control pTK-Renilla Lucifearse plasmid and 1 mg of
the reporter plasmids were cotransfected into 293 T cells. After
24 hours, cells were treated with 100 IU of IL-2 overnight and
assayed for luciferase activity. Luciferase assays were performed by
using the Dual-Glo luciferase kit (Promega, UK) according to the
manufacturer’s instructions. To normalize for transfection effi-
ciency, luciferase activity was divided by the Renilla luciferase
activity, which gave a relative luciferase activity for each sample.
Further, the IL-2 induced value is divided by the uninduced value
to give a fold induction.
Results and Discussion
Identification of STAT5 regulated genes
In vivo STAT5 targets in human activated CD4 T cells were
identified by ChIP, followed by cloning and sequencing. A total of
105 unique binding sites were mapped and assigned to the genome
(Table S1). The genomic distribution of STAT5 binding sites were
analysed with respect to an annotated gene as being present within
introns, or, ,10 kb upstream of the gene and in intergenic regions
(here defined as regions .10 kb from the 59 end of the two closest
FRA2 Is Regulated by IL-2
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annotated genes on a chromosome). Thus, for STAT5 target sites
located ,10 kb upstream of a gene, the closest gene was
considered as a potential regulatory target. For fragments mapping
to an intron, the corresponding gene was designated the potential
STAT5 target gene and for intergenic binding sites, both the genes
involved were considered as potential targets.
Of the 105 unique cloned inserts isolated from activated CD4 T
cells, greater than one third (42%) of the fragments lie within
introns of annotated genes, with a larger percentage within intron
1 (13%). A significant number of binding sites (49, 47%)
correspond to intergenic regions, while 12 of the fragments
(11%) were within 10 kb upstream of a gene (Figure 1). These
findings predict that generally STAT5 binds within enhancer
rather than promoter regions and facilitates transcription through
long distance interactions by DNA looping [19]. ChIP-seq studies
on STAT1 and NF-kB are consistent with these findings and
demonstrate that the percentage of binding sites in intergenic or
intronic regions far exceeds those in the promoters of genes
[20,21]. Studies of other transcription factors have shown that
binding sites can be as far as 168 kb and 206 kb upstream of a
transcription start site [22].
Further, an in silico analysis of the clones was performed to
investigate the presence of STAT5 recognition motifs
TTCN3GAA and TTN5AA. The consensus GAS recognition
motif for dimeric STAT5 binding is TTCN3GAA [23]. However,
STAT5 can also potentially recognize the more general consensus
TTN5AA, when it binds DNA as a tetrameric complex of N-
domain linked dimers [23]. The motifs were subdivided into three
groups: clones containing TTCN3GAA sites, clones containing
TTN5AA sites and those containing no GAS motifs. The results
are summarized as a pie-chart in Figure 2. The striking
observation for this analysis was that the majority of the sequences
contained the more general TTN5AA sequence, rather than the
consensus GAS motif, TTCN3GAA, perhaps indicating a less
stringent requirement for DNA recognition, reminiscent of DNA
binding by tetrameric STAT5 complexes. Several clones had
multiple GAS motifs of either type. In view of this observation, it is
interesting to note previous studies that have shown strengthening
by virtue of the protein-protein interactions mediated via the N-
domains, whereby tetrameric STAT5 complexes can specifically
bind to tandem-linked non-consensus or non-GAS motifs in
addition to consensus GAS motifs, thus increasing the repertoire of
STAT5-regulated genes [18]. Two other STAT5-ChIP-cloning
studies have also observed use of only the TTN5AA sequences [7],
while studies of other transcription factors have noted the use of
similar non-consensus recognition motifs [24]. These findings are
consistent with the recent demonstration that the STAT5 tetramer
plays a critical role in the cytokine responses of normal immune
function and in the resistance to malignant transformation of cells
[25,26]. Consistent with previous observations from in-vitro
STAT5 binding studies, a small number of the putative STAT5-
binding sites did not contain a recognizable GAS motif (23).
Similar results have been obtained for other transcription factors
and other STAT5-ChIP studies where it was observed that the
frequency of factors not binding to consensus sequences was very
high [24]. Taken together, STAT5 appears to favor the less
stringent general consensus GAS motif, for in-vivo DNA binding,
which would potentially be bound by tetrameric STAT5.
Although an in-silico analysis of the target binding sites
enhanced our knowledge of potential STAT5-regulated genes,
they are in need of experimental validations and functional studies.
Verification of the robustness of the ChIP assay was confirmed by
independent ChIP-PCR analysis on the target sites which
demonstrated that they were bonafide STAT5 binding sites.
Although the genes associated with the putative STAT5 binding
sites have not all been confirmed as being bonafide STAT5
regulated genes, they were classified into functional categories to
gain insight into the cellular functions that could potentially be
regulated by STAT5 in activated CD4+ T cells. One important
caveat to this analysis is that, where a particular binding site could
not be annotated to a single gene, as in the case of intergenic sites,
both flanking genes were considered in the functional classifica-
tion. They were categorized using the PANTHER database
(Figure 3A and 3B). The functional categories predicted from this
analysis included metabolic, cellular, cell communication, devel-
opmental, immune system, cell cycle, transport and apoptosis.
While many of the predicted functions from this analysis are
consistent with known functions of STAT5, for instance cell cycle,
differentiation, survival, signal transduction, others such as cell
adhesion, transport and metabolism are novel functions predicted
from this study.
The molecular functional categories of target sites that were
most highly represented in activated CD4+ T cells were genes
Figure 1. The locations of putative STAT5 binding sites in
activated CD4+ T cells. Mapping of STAT5 binding sites relative to
annotated genes were categorized into four groups. Intergenic region
denotes binding sites present greater than 10 kb away from both
flanking genes. ,10 kb upsteam denotes the region less than 10 kb
upstream of the 59 region of the nearest gene. Internal intron denotes
introns other than intron 1 of the gene and intron 1 depicts the
presence of a binding site within the first intron of the gene.
doi:10.1371/journal.pone.0090370.g001
Figure 2. STAT5 motif analysis of the mapped ChIP clones in
activated CD4+ T cells. Out of the 105 binding sites for activated
CD4+ T cells immunoprecipitated with anti-STAT5 Ab, 68% had TTN5AA
motifs and TTCN3GAA sites were present in 26% of the target sites. The
labels denote the category name and percentage.
doi:10.1371/journal.pone.0090370.g002
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encoding binding, catalytic activity, receptors, transcription,
enzymes and proteins involved in cell differentiation, proliferation
and survival. Consistent with the known association of aberrant
constitutive activation of STAT5 with human cancers/tumours of
haematological and non-haematological origins, several potential
oncogenes were identified as putative downstream target genes.
These include, TLE4 [27], ACSL6 [28], TOP1 [28], TCEA1,
TSC22D1[29], KIF1A [30], HERC2[30], LRP1B [31], CDH10
[32,33], ST6GAL2[32], FAT1[33], CHD1[34], GRID1[35,36],
IGFBP3[35], ADAM22[37], CHD6 [38] and and FRA2 [15]. Thus,
the functional classification of potential STAT5-regulated genes
confirmed known functions of STAT5 and furthermore provided
novel insight into potential unknown cellular functions and
oncogenes regulated by these proteins. Of these, we chose to
further characterize FRA2 in this study, as this gene seemed
particularly interesting in light of the fact that FRA2 is not only
associated with malignant transformation, but is also a key
regulator of CD4 T cell differentiation, both of which are known
activities of STAT5 [11,15].
Interestingly, FRA2 was also identified in a STAT5-ChIP study
from IL-3 stimulated BAF3 cells, suggesting that it is an important
downstream mediator of STAT5 function, irrespective of the
activating cytokine [39].
In Silico analysis of FRA2 locus in CD4+ T cells
The cloned sequence that mapped to an internal intron within
the FRA2 gene contained a consensus GAS sequence, TTCTGA-
GAA and one other TTN5AA sequence: TTGGAGCAA (GAS1,
Figure 4A).
Figure 3. Gene ontologies of putative STAT5 targets from activated CD4+T cells. Gene function of putative binding sites is based on the
summary information provided in the PANTHER database. Out of the 105 binding sites identified, functional categorisation was done for 104 genes,
out of which 99 could be classified and the remaining 5 genes were of unknown/uncategorized function. Those 99 genes were classified based on
their molecular function (A) and biological processes (B). In some instances, a given gene was represented in more than one category (for example,
FRA2 was incorporated under the binding (GO:0005488) as well as transcriptional regulator activity (GO: 0030528) molecular functions).
doi:10.1371/journal.pone.0090370.g003
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To further explore the mechanism of FRA2 regulation by
STAT5, the 59 upstream regulatory region was scanned for GAS
sequences located either within or near to hypersensitive sites,
identified by the CD4 DHS study [40]. One additional DHS site
was identified, which contained a GAS motif (GAS2). A schematic
figure representing the GAS sequences studied is shown
(Figure 4B). While GAS1 represents the sequence present within
the identified clone in intron 3 of the FRA2 gene, GAS2 represents
the scanned GAS sequence present within the 59 TSS. GAS 1
mapped to chromosome 2 at +17850 to +18554 bp (Intron 3) and
GAS2 mapped to chromosome 2 at 23108 to 22820 bp
upstream (TSS) of the FRA2 gene, both of which contained a
consensus GAS motif.
To determine whether the FRA2 GAS (GAS1 and GAS2)
sequences within the cloned site and promoter region are direct
targets of STAT5, quantitative real-time ChIP-PCR was per-
formed on chromatin obtained by ChIP of IL-2-stimulated (or
untreated control) PHA-activated human CD4 T cells. Specific
primers encompassing the GAS fragments were used and the
ChIP was performed using an anti-STAT5 antibody or IgG
Figure 4. Study of the binding site, location and validation of the cloned fragment obtained by ChIP. A. Sequence of the cloned
fragment and the corresponding typical and atypical GAS sequences present. There is a TTN5AA (blue font) sequence and one typical GAS TTCN3GAA
(red font) sequence present within the cloned fragment. B. The relative location of the cloned fragment, GAS1 and GAS2 with respect to the FRA2
transcription start site (TSS) and intron/exon is shown schematically and its coordinates on the UCSC genome browser. Figure 4C: IL-2 induces in-vivo
binding of STAT5 to GAS1 within the third intron of the FRA2 gene in preactivated CD4 T cells. STAT5-ChIP samples from 6IL-2-treated preactivated
CD4 T cells were analysed by real-time PCR for specific binding to the two GAS motifs identified above. ChIP assay was performed using the
LowCell# ChIP kit and 6IL-2-treated preactivated CD4 T cells. Enrichment of GAS 1 was higher when compared to GAS 2 and more so with the
STAT5b antibody.
doi:10.1371/journal.pone.0090370.g004
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control. Enrichment of both GAS1 and GAS2 was observed,
although the binding specificity was noticeably higher for the
cloned GAS1 site, which also shows a greater enrichment for
STAT5b as compared to STAT5a (Figure 4C). Enrichment of the
STAT5 binding site was observed for chromatin that was
immunoprecipitated with STAT5a and STAT5b antibody in the
presence of IL-2 when compared to unstimulated and IgG control.
Thus, IL-2 induces specific binding enrichment of STAT5b
primarily to a region in the intron of the FRA2 locus.
The FRA2 cloned fragment, when queried for its location with
respect to the genome-wide DNase HS (DHS) sites in CD4+ T
cells (UCSC Genome Browser on Human May 2004 Assembly,
hg17) [40], demonstrated that it is located within a DNase
hypersensitive site. Genome wide studies into histone modifica-
tions by acetylation and methylation on CD4 T cells has provided
Figure 5. Custom Track View of DNase I hypersensitive sites (DHS) sites. DHS sites, Pol II, H3K20me1, H3K4me3, H3K4me2, H3K4me1,
H2BK5me1 and H2A.Z along the FRA2 gene on Chr 2 were obtained from the UCSC Genome Browser.
doi:10.1371/journal.pone.0090370.g005
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valuable insights into the activation, repression or silencing of
genes in these cells [41,42]. Acetylation of histones, which is
invariably associated with gene activation, is regulated by various
methylations (position and state) of the lysine and arginine residues
on histone tails to dictate either an activation or repression of
genes [43,44,45]. Some of the methylation marks associated with
activation are H2BK5me1, H3K4me1, H3K4me2, H3K4me3,
and H4K20me1. A study of the methylation pattern available on
the UCSC genome browser also suggests FRA2 is a transcription-
ally active gene in CD4+ T cells (Figure 5). The FRA2 gene also
contains regions of enrichment of the H2 variant, H2A.Z, which is
often associated with nucleosome instability (Figure 5)(43). This
would indicate that the chromatin in the FRA2 locus is
transcriptionally active, because the GAS motifs are located
within DHSs [40]. Thus, this locus appears to be ‘‘poised’’ for
transcriptional activation in unactivated CD4 T cells.
Mining for STAT5 target sites on the FRA2 gene was done
using massive parallel sequencing (ChIP-Seq) data already
available, which defines the genome-wide targets of STAT5A
and STAT5B in CD4+ T cells. The data is available via the Gene
Expression Omnibus (GEO), accession number GSM671400 and
GSM671402 at www.ncbi.nlm.nih.gov/geo. Peaks for STAT5b
binding to a region within intron 3 of the FRA2 gene was observed
at chr2:28,485,399-28,485,970 on the UCSC genome browser
(Human Mar. 2006 (NCBI36/hg18) Assembly). This region is
located close to GAS1 identified in this study which maps to the
genome base position of Chr2:28,487,132-28,487,836. The site
identified by the ChIP-seq study and the present study are almost
1200 bp away from each other and it is possible that DNA binding
sites were juxtaposed by DNA looping to functionally interact and
orchestrate transcriptional activation.
FRA2 is expressed in activated CD4+ T cells and is
regulated by IL-2
To investigate whether IL-2 can induce FRA2 gene expression,
CD4 T cells were preactivated with PHA to achieve maximal IL-2
responsiveness by expressing the high affinity IL-2 receptor,
followed by treatment with IL-2 for various times (2–24 hours) or
left untreated before RNA was extracted and FRA2 expression was
analysed by quantitative real-time PCR (qRT-PCR). These studies
revealed that FRA2 is induced in a biphasic manner by IL-2 in
activated CD4 T cells: with peak expression at approximately
4 hours, decreasing to basal levels within 12 hours and with a
second peak at 24 hours (Figure 6). Thus, exogenous IL-2 alone
efficiently stimulates FRA2 expression in the presence of TCR
stimulation.
TCR plus CD28-mediated induction of FRA2 is dependent
on IL-2R signaling
To dissect the contribution of IL-2 receptor signaling to the
TCR-induced expression of FRA2, the effect of clinically-
Figure 6. IL-2 regulates expression of FRA2. Quantitative RT-PCR
was performed on PHA activated CD4+ T cells stimulated with or
without IL-2 for different times to evaluate the expression of FRA2.
Expression levels are presented as fold increase (logarithmic scale) and
compared to the baseline levels (cells not treated with IL-2). 18 s was
used as the housekeeping gene and served as the endogenous control.
IL-2 stimulation strongly induced FRA2 expression with two peaks
observed at 4–6 hours and 24 hours post stimulation. This is
representative of at least three independent experiments performed
in triplicate.
doi:10.1371/journal.pone.0090370.g006
Figure 7. TCR induced FRA2 expression is dependent on IL-2
signaling. CD4+ T cells were TCR activated 6HAT (humanized anti-Tac
antibody) treatment and mRNA was prepared pre- and 17 hours post-
stimulation. qRT-PCR analysis for FRA2 expression was carried out. TCR
activation induces FRA2 expression, which is abrogated by the addition
of HAT, indicating that IL-2R function is essential for induction of FRA2.
This is representative of at least three independent experiments
performed in triplicate.
doi:10.1371/journal.pone.0090370.g007
Figure 8. Activation of the JAK3-STAT5 pathway is essential for
the induction of FRA2 gene expression by TCR activation. CD4+
T cells were stimulated via the TCR 6 the JAK3 inhibitor R333, RNA was
prepared four hours post treatment. qRT-PCR analysis was performed to
detect the relative expression of FRA2. FRA2 gene expression was
induced by TCR activation and abrogated by R333 treatment. Shown is
a representative experiment performed in triplicate and repeated three
times.
doi:10.1371/journal.pone.0090370.g008
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important inhibitors of CD25 and JAK3 on this process were
examined. Cells were stimulated with anti-CD3 and anti-CD28
antibody, for specific T cell receptor activation which leads to IL-2
production. The human interleukin 2 receptor alpha (IL2Ra) is
also known as CD25 and HAT blocks IL-2 signalling. Human
CD4+ T cells were isolated from buffy coats and stimulated with
anti-CD3 and anti-CD28 antibodies for 17 hours in the presence
or absence of humanized anti-Tac (HAT) antibody (Daclizumab,
anti-CD25). It has previously been shown that HAT treatment
efficiently blocks JAK3/STAT5 activation and consequent pro-
duction of Th1 and Th2 cytokines following anti-CD3 and anti-
CD28 antibody stimulation of PBMC [46]. Here TCR activation
induced FRA2 expression 17 hours after stimulation, which was
abolished in the presence of HAT. Thus, the TCR induced
activation of FRA2 is dependent on IL-2/IL-2R signaling
(Figure 7).
To confirm that induction of FRA2 by T cell activation was
specifically due to the activation of the JAK3/STAT5 pathway, a
JAK3 inhibitor R333 [47], was employed during TCR activation.
CD4 T cells were purified and stimulated with anti-CD3 and anti-
CD28 antibodies in the presence or absence of R333. RNA was
prepared from the samples and analysed by real-time PCR for
FRA2 expression. The data showed that TCR-mediated activation
of CD4 T cells induced FRA2, 17 hours post stimulation, which
was abrogated in the presence of the JAK3 inhibitor (Figure 8).
Taken together, the data indicate that TCR-induced upregulation
of FRA2 gene expression is dependent on IL-2-signaling in CD4 T
cells.
STAT5 binding site, GAS1 exerts regulatory activities
To confirm that the GAS1 sequence can induce STAT5-
dependent transcriptional activity, a luciferase reporter assay was
performed using an IL-2R reconstitution system, as previously
described [18]. These studies revealed that IL-2-induced luciferase
expression from a GAS1 driven reporter construct could be
activated by transfection of STAT5a or STAT5b alone when
compared to the empty vector transfected negative control, which
shows no IL-2 inducible transcriptional activation of luciferase
activity (Figure 9). Interestingly, consistent with the ChIP-PCR
results, STAT5b was able to induce higher levels of luciferase
activity as compared to STAT5a. Co-expression of STAT5a and
STAT5b did not significantly differ from the results obtained with
either STAT5a and STAT5b alone. These data confirm those
from previous studies on optimal GAS binding sites for STAT5,
which reveal a favoured consensus sequence of TTC(C/T)N(G/
A)GAA [23,48,49], as in GAS1 and are also consistent with the
relative STAT5 binding enrichment for the two GAS motifs by
ChIP (Figure 4C). Taken together the findings show that IL-2
induces specific STAT5 binding and transcriptional activation
from an intronic GAS motif of the FRA2 gene.
Conclusion
In this study, ChIP was used to generate a library of STAT5
regulated genes from activated human CD4 T cells stimulated
with IL-2. Analysis of 105 putative STAT5 binding sites isolated,
for their location with respect to TSS of genes, showed that the
majority of the sites mapped to introns and intergenic regions,
which is consistent with the findings of whole genome analysis of
DNAse-1 hypersensitive sites [50]. Although the consensus GAS
recognition motif for dimeric STAT5 binding is TTCN3GAA
[23], a large proportion of the sites contained the more general
consensus TTN5AA. Gene annotation studies predicted a number
of cellular functions regulated by STAT5, many of which were
previously known but also exposed novel functions such as those
related to metabolism and transport. The main disease prediction
from the analysis of these STAT5-target genes is cancer, which
correlates with previous studies of malignancies [51,52,53,54].
FRA2 is an example of one such tumor associated gene, whose
regulation by STAT5 was studied here. The intronic STAT5
binding site in FRA2 contained a consensus motif, TTCN3GAA
and was located in an architectural region of chromatin that is
poised for transcriptional activation. Previous studies have shown
that FRA2 is expressed at the protein level during early Th2 cell
polarization [11], and that FRA2 is a putative STAT5 target gene
[39]. Our studies extend these observations to reveal that the
FRA2 locus is in a poised chromatin state, enabling expression
early during T cell activation in an IL-2 dependent manner.
Interestingly, IL-2/STAT5, like FRA2 is known to inhibit Th17
differentiation, and therefore the characterization of FRA2 as a
STAT5 target gene in this study may be one mechanism by which
STAT5 can negatively regulate TH17 differentiation. Its role in T
cell differentiation needs to be studied further.
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